J J Fulmer. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Cost-Benefit AnalysisHumansOsteomyelitis/drug therapyOsteomyelitis/economics
Year: 1994 PMID: 7996301 DOI: 10.1007/BF02599233
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 5.128